Nestle aims to shed skin unit to focus on food,
nutrition
Send a link to a friend
[September 20, 2018]
By Martinne Geller and John Revill
LONDON/ZURICH (Reuters) - Nestle <NESN.S>
put its skin health unit up for sale on Thursday, as the maker of
Nescafe and Perrier water ditches underperforming businesses and fends
off criticism from an activist investor demanding an overhaul.
Nestle said it was exploring strategic options for the unit, saying "the
future growth opportunities of Nestle Skin Health lie increasingly
outside the group's strategic scope" and did not fit in with a sharper
focus on food, drinks and nutritional health.
Nestle agreed this week to sell its Gerber Life Insurance business for
$1.55 billion, while sources told Reuters it was also bidding for
GlaxoSmithKline's <GSK.L> Horlicks drink.
The skin health unit makes Cetaphil and Proactiv skin care brands,
Restylane wrinkle fillers and prescription dermatology treatments. It
had sales of 2.7 billion Swiss francs ($2.8 billion) last year,
accounting for about 3 percent of Nestle's total.
Vontobel analyst Jean-Philippe Bertschy estimated the business was worth
6 billion to 6.5 billion francs, excluding financial debt, provisions
and deferred taxes. He said it could fetch between 6 billion and 8
billion francs in a sale. Another analyst put the sale value at about 7
billion francs.
Nestle Skin Health was formed in 2014 when Nestle bought L'Oreal's <OREP.PA>
stake in their Galderma dermatology venture.
Jefferies analyst Martin Deboo said the most likely exit options were a
leveraged buyout or a sale to L'Oreal, if the French cosmetics firm
followed Nestle in making a strategic U-turn.
L'Oreal, in which Nestle is a shareholder, declined to comment.
UNDER PRESSURE
Nestle, the world's largest packaged food company, is under pressure
from Third Point, a hedge fund run by investor Daniel Loeb, to take bold
moves to improve returns.
Chief Executive Mark Schneider, the first externally hired CEO in nearly
a century, has addressed several of Third Point's demands, including
setting a margin target and speeding up acquisitions and divestitures.
The one demand he has not addressed is the sale of Nestle's 23 percent
stake in L'Oreal, worth nearly 26 billion euros.
Baader Helvea analyst Andreas von Arx said the plan to exit skin health
could reignite talk about the stake since that also lay outside the
vision Nestle outlined on Thursday.
[to top of second column] |
The Nestle logo is seen during the opening of the 151st Annual
General Meeting of Nestle in Lausanne, Switzerland April 12, 2018.
REUTERS/Pierre Albouy/File Photo
"Sharpening our strategic focus on Nestle's core food, beverage and nutritional
health products offers the best opportunity for long-term profitable growth and
is fully in line with the pursuit of our company's purpose," said Paul Bulcke,
Nestle's chairman and former CEO.
VOLTE-FACE
When Bulcke ran Nestle, skin treatments were a major part of a push into higher
growth and more profitable health products taken to counter a slowdown in its
traditional food businesses.
But the unit has performed poorly, incurring one-off costs including inventory
writedowns and a significant goodwill impairment this year. Last year, Nestle
started restructuring the business, cutting jobs and closing a factory.
Divesting the business represents a symbolic break with the decisions of
Schneider's predecessors, Jefferies' Deboo said.
"This in turn suggests that Schneider is being given full latitude to act in the
interests of shareholder value, unbounded by the decisions of the past," he
said.
Exiting skin health is something many analysts and investors had asked for,
Baader Helvea's von Arx said, adding that it put Nestle "fully on track" to
deliver on Schneider's promise last September to swap out as much as 10 percent
of its portfolio.
Nestle has also sold its U.S. confectionery unit, and has done several deals in
coffee, involving Starbucks <SBUX.O> and Blue Bottle.
The skin health review is due to be completed by mid-2019.
At the same time, Nestle said it remained committed to its health science unit,
which sells medical nutritional products and bulked up with the purchase of a
vitamin business this year.
Nestle shares were up nearly 1 percent at 1049 GMT.
($1 = 0.9668 Swiss francs)
(Additional reporting by Sarah White in Paris; Editing by Sherry Jacob-Phillips
and Edmund Blair)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |